Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2001

View Archived Issues

U.S. FDA reviews sample of new drugs approved last year

SuperGen obtains certain rights to VTA technology

Q2 2001 at Neurochem marked by completion of proof-of-concept study for AD compound

Maxim receives SBIR grants for evaluation of anticancer agents

Long-acting contraceptive launched by Berlex in U.S.

Genzyme Transgenics to produce Atlantic's ABI-001

Blockade of alpha4 integrin provides significant neuroprotection in animal models of stroke

Okayama University scientists investigate role of PARP in post-SAH cerebral vasospasm

Neuroprotection provided by new antioxidant manganese complexes

Merck's new oligopeptide-cytotoxic agent conjugates useful for Rx of cancer, BPH

New therapeutic option for allergies available from UCB in Germany

Joint research at Ortho-McNeil and Cor leads to new peptoid/peptidomimetic PAR-1 antagonists

Pyrimidine-based protein tyrosine kinase inhibitors and their use described by Merck

Bayer patents new series of potassium channel blockers especially for dementia and depression

Triazole and imidazole derivatives from Roche are NMDA subtype-selective blockers

Antagonists at 5-HT2B/5-HT2C receptors designed at ADIR

Toleragen candidate for APS reduces disease-causing antibodies, corrects clotting defect in animals

IGT Pharma/Neurotrophic Bioscience merger nears completion

Teva finalizes separate agreements with Aventis and Lundbeck

Patient enrollment complete in phase IIb trial of IL-2 gene medicine for H&N cancer

FDA advisory committee recommends approval of injectable ziprasidone

TOPAS trial evaluates different doses of certoparin in acute ischemic stroke patients

Questcor licenses novel antifungal technology to Tularik

SIGA Technologies reports clinical trial results for vaccine delivery technology

GenVec begins phase I clinical trial with TNFerade

Melacine now available in Canada for treatment of stage IV melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...